Cellink AB (publ) has completed private placements of shares through an accelerated book building procedure, performed by Carnegie Investment Bank and J.P. Morgan Securities as Joint Global Coordinators and Joint Bookrunners, raising SEK 946 million before transaction costs.

The purpose of the private placements of shares is to finance the acquisition of Scienion AG, and to create further room for a continued M&A agenda. In addition to a strong support from existing shareholders, several new institutional investors participated in the private placements.

Cellink is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing.

Carnegie Investment Bank and J.P. Morgan Securities acted as Joint Global Coordinators and Joint Bookrunners in connection with the transactions. Baker McKenzie acted as Swedish and U.S. legal adviser to the Joint Global Coordinators and Joint Bookrunners.

Baker McKenzie's team consisted of Joakim Falkner, Henric Roth, Olof Larsson and Marlene Wiklund from the firm's Stockholm office, and Megan Schellinger and Adam Farlow from the firm’s London office.


Explore Our Newsroom